Lung Cancer Clinical Trials in Los Angeles

Showing 421-440 of 509 trials

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

NCT01858389

This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each two-week cycle to patients with Non-small cell lung cancer. The study includes two groups of patients, those whose tumor has a documented T790M mutation, and those without this mutation. All patients will receive repeated cycles of dacomitinib until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met.

Non-small Cell Lung Cancer

Pfizer41 participantsStarted Jul 2013

Beverly Hills, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +11 more locations

COMPLETED< 1 mile

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

NCT01414595

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies tissue samples from patients with non-small cell lung cancer.

Lung Cancer

Alliance for Clinical Trials in Oncology248 participantsStarted Mar 2012

Los Angeles, California, United States • Lewes, Delaware, United States • Newark, Delaware, United States +8 more locations

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer

Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Other Conditions in Los Angeles